22 Recruiting Studies Using Alpelisib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Alpelisib
Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)
📍 Boston Childrens Hospital — Boston, Massachusetts
PIK3CA-related Overgrowth Spectrum (PROS)
View Study & Checklist ➔Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
📍 Novartis Investigative Site — Sint-Niklaas, Oost Vlaanderen
Breast Cancer
View Study & Checklist ➔Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
📍 University of Alabama at Birmingham — Birmingham, Alabama
Breast Cancer
View Study & Checklist ➔Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
📍 Dothan Hematology and Oncology — Dothan, Alabama
Breast Cancer
View Study & Checklist ➔Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
📍 Highlands Oncology Group — Fayetteville, Arkansas
Advanced HER2+Breast Cancer
View Study & Checklist ➔24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs
📍 Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Vascular Anomalies
View Study & Checklist ➔Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Breast Cancer
View Study & Checklist ➔Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
📍 University of Colorado Cancer Center — Aurora, Colorado
HER2-positive Metastatic Breast Cancer
View Study & Checklist ➔Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
📍 UCSF Birthmarks and Vascular Center — San Francisco, California
PIK3CA-related Overgrowth Spectrum (PROS)
View Study & Checklist ➔Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
📍 The University of Kansas Clinical Research Center — Fairway, Kansas
Breast Cancer
View Study & Checklist ➔A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Breast Cancer
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
📍 Cancer Blood and Specialty Clinic — Los Alamitos, California
Breast Cancer
View Study & Checklist ➔Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
📍 University of Illinois Cancer Center — Chicago, Illinois
Hormone Receptor Positive Breast Carcinoma
View Study & Checklist ➔A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
📍 City of Hope — Duarte, California
Endometroid Endometrial Cancer
View Study & Checklist ➔Alpelisib Challenge Test (ACT)
📍 Columbia University Irving Medical Center — New York, New York
Insulin Resistance
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
📍 UCSF Benioff Children s Hospital — Oakland, California
Lymphatic Malformations
View Study & Checklist ➔Human Models of Selective Insulin Resistance: Alpelisib, Part I
📍 Columbia University Irving Medical Center — New York, New York
Insulin Resistance
View Study & Checklist ➔Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
📍 MD Anderson Cancer Center — Houston, Texas
Melanoma (Skin Cancer)
View Study & Checklist ➔EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
📍 Washington University — St Louis, Missouri
PIK3CA-related Overgrowth Spectrum (PROS)
View Study & Checklist ➔Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Metastatic Breast Cancer
View Study & Checklist ➔Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
📍 Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
Advanced Breast Cancer
View Study & Checklist ➔